Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,457.00    6.00 (0.41%)
Bid:
1,464.00
Ask:
1,466.00
Spread: 2.00 (0.137%)
Market Cap: £3.08b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Stabilisation Notice

31 Mar 2015 15:27

RNS Number : 0377J
Citigroup Global Markets Limited
31 March 2015
 

31st March 2015

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

Hikma Pharmaceuticals PLC

Stabilisation Notice

Citigroup Global Markets Limited. (contact: Syndicate Desk 0207 986 9000) hereby gives notice that the Stabilising Manager(s) named below may stabilise the offer of the following securities in accordance with Commission Regulation (EC) No. 2273/2003 implementing the Market Abuse Directive (2003/6/EC).

The securities:

Issuer:

Hikma Pharmaceuticals PLC

Guarantor (if any):

Aggregate nominal amount:

$ TBC

Description:

Reg S registered

Offer price:

TBC

Other offer terms

TBC

Stabilisation:

Stabilising Manager(s):

 Citigroup Global Markets Limited

 

Stabilisation period expected to start on:

1st April 2015

Stabilisation period expected to end no later than:

1st May 2015 (30 days after the proposed issue date of the securities)

Maximum size of over-allotment facility:

5% of the aggregate nominal amount stated above.

 

In connection with the offer of the above securities, the Stabilising Manager(s) may over-allot the securities or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. However, there is no assurance that the Stabilising Manager(s) will take any stabilisation action and any stabilisation action, if begun, may be ended at any time.

 

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

 

This announcement and the offer of the securities to which it relates are directed only at persons outside the United Kingdom and persons in the United Kingdom who have professional experience in matters related to investments or who are high net worth persons within article 12(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and must not be acted on or relied on by other persons in the United Kingdom.

 

In addition, if and to the extent that this announcement is communicated in, or the offer of the securities to which it relates is made in, any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the "Prospectus Directive") before the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Member State in accordance with the Prospectus Directive (or which has been approved by a competent authority in another Member State and notified to the competent authority in that Member State in accordance with the Prospectus Directive), this announcement and the offer are only addressed to and directed at persons in that Member State who are qualified investors within the meaning of the Prospectus Directive (or who are other persons to whom the offer may lawfully be addressed) and must not be acted on or relied on by other persons in that Member State.

 

This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offer of securities in the United States.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STAJBMITMBTJBFA
Date   Source Headline
30th Nov 20227:00 amRNSHikma Injectables Portugal site visit
22nd Nov 202211:38 amRNSHolding(s) in Company
17th Nov 20229:50 amRNSHolding(s) in Company
3rd Nov 20227:00 amRNSTrading Statement
13th Oct 20223:00 pmRNSDirectorate Change
5th Oct 202212:16 pmRNSHolding(s) in Company
4th Oct 202210:05 amRNSHolding(s) in Company
3rd Oct 20223:52 pmRNSBlock listing Interim Review
3rd Oct 20223:11 pmRNSTotal Voting Rights
30th Sep 20227:00 amRNSDirector changes and update on AGM 2022 resolution
14th Sep 20229:19 amRNSChange of Hikma interim dividend payment date
1st Sep 20222:25 pmRNSTotal Voting Rights
30th Aug 202212:22 pmRNSHikma launches RYALTRIS
23rd Aug 20223:12 pmRNSDirector/PDMR Shareholding
4th Aug 20227:00 amRNSHalf-year Report
1st Aug 20224:48 pmRNSTotal Voting Rights
18th Jul 20229:26 amRNSNotice of Results
1st Jul 202210:52 amRNSTotal Voting Rights
15th Jun 20223:00 pmRNSCompany Secretary Change
15th Jun 20221:46 pmRNSDirector/PDMR Shareholding
10th Jun 20226:08 pmRNSTransaction in Own Shares
9th Jun 20225:14 pmRNSTransaction in Own Shares
8th Jun 20225:15 pmRNSTransaction in Own Shares
7th Jun 20225:13 pmRNSTransaction in Own Shares
6th Jun 20225:14 pmRNSTransaction in Own Shares
1st Jun 20226:08 pmRNSTransaction in Own Shares
31st May 20225:52 pmRNSTransaction in Own Shares
31st May 202210:00 amRNSDirector/PDMR Shareholding
30th May 20225:23 pmRNSTransaction in Own Shares
27th May 20225:20 pmRNSTransaction in Own Shares
26th May 20225:20 pmRNSTransaction in Own Shares
25th May 20226:03 pmRNSTransaction in Own Shares
24th May 20225:53 pmRNSTransaction in Own Shares
24th May 20227:00 amRNSSiggi Olafsson to step down as Chief Executive
23rd May 20225:51 pmRNSTransaction in Own Shares
20th May 20225:37 pmRNSTransaction in Own Shares
20th May 202212:58 pmRNSResults of EGM
19th May 20226:15 pmRNSTransaction in Own Shares
18th May 20225:22 pmRNSTransaction in Own Shares
17th May 20225:49 pmRNSTransaction in Own Shares
16th May 20226:05 pmRNSTransaction in Own Shares
13th May 20225:41 pmRNSTransaction in Own Shares
12th May 20225:35 pmRNSTransaction in Own Shares
11th May 20225:19 pmRNSTransaction in Own Shares
11th May 20227:00 amRNSShare Buyback Programme
10th May 20225:18 pmRNSTransaction in Own Shares
9th May 20225:59 pmRNSTransaction in Own Shares
6th May 20225:54 pmRNSTransaction in Own Shares
5th May 20225:47 pmRNSTransaction in Own Shares
5th May 20227:00 amRNSHikma updates Generics guidance for 2022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.